Ubs Group Ag Ayala Pharmaceuticals, Inc. Transaction History

Ubs Group Ag

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 08, 2023	BUY	$0.38 - $0.71 $383 - $717	1,010 New	1,010 $0
Q2 2022 Aug 10, 2022	BUY	$0.99 - $4.15 $2,463 - $10,325	2,488 New	2,488 $3,000
Q4 2021 Feb 14, 2022	SELL	$8.32 - $12.45 $3,585 - $5,365	-431 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$8.13 - $14.09 $41,284 - $71,549	-5,078 Reduced 92.18%	431 $5,000
Q2 2021 Aug 13, 2021	BUY	$9.2 - $11.3 $39,946 - $49,064	4,342 Added 372.07%	5,509 $56,000
Q1 2021 May 12, 2021	BUY	$10.72 - $22.0 $11,513 - $23,628	1,074 Added 1154.84%	1,167 $13,000
Q4 2020 Feb 11, 2021	SELL	$9.67 - $13.5 $3,133 - $4,374	-324 Reduced 77.7%	93 $1,000
Q3 2020 Nov 12, 2020	BUY	$8.8 - $14.55 $3,669 - $6,067	417 New	417 $5,000

Ticker AYLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 14,833,300
Description
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinic...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.